Holen Sie sich die Stockscreener-App
7.33
0.14%
-0.010
Handel nachbörslich:
7.31
-0.02
-0.27%
Schlusskurs vom Vortag:
$7.34
Offen:
$7.31
24-Stunden-Volumen:
1.23M
Relative Volume:
0.81
Marktkapitalisierung:
$433.18M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
139.89
EPS:
0.0524
Netto-Cashflow:
$12.42M
1W Leistung:
-11.15%
1M Leistung:
+20.96%
6M Leistung:
+46.02%
1J Leistung:
+57.63%
1-Tages-Spanne:
$7.26
$7.53
1-Wochen-Bereich:
$7.26
$8.55
52-Wochen-Spanne:
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vergleichen Sie VNDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.33 | 433.77M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
What sentiment indicators say about Vanda Pharmaceuticals Inc. stockMarket Sentiment Summary & Weekly High Potential Stock Alerts - ulpravda.ru
Published on: 2026-01-08 21:09:38 - ulpravda.ru
Can Vanda Pharmaceuticals Inc. (VM4) stock surprise markets with earningsJuly 2025 Spike Watch & Reliable Breakout Forecasts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock affected by interest rate hikes2025 Historical Comparison & Fast Entry and Exit Trade Plans - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock positioned well for digital economyEarnings Recap Report & Reliable Entry Point Alerts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. (VM4) stock good for long term investingWeekly Risk Report & Low Drawdown Trading Techniques - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application - GuruFocus
FDA rejects Vanda's jet lag drug application days after approving motion sickness drug - The Business Journals
How Vanda Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Sector Moves & Low Risk High Win Rate Picks - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces Setback with FDA Rejection - GuruFocus
Vanda falls as FDA rejects jet lag drug (VNDA:NASDAQ) - Seeking Alpha
Vanda Pharmaceuticals (VNDA) Shares Fall After FDA Decision - GuruFocus
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application - TipRanks
Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application - Stocktwits
Vanda Pharmaceuticals stock falls after FDA rejects jet lag treatment application - Investing.com UK
Vanda Pharmaceuticals Inc Receives FDA Decision on HETLIOZ® sNDA for Jet Lag - TradingView — Track All Markets
FDA pushes back on new drug that aimed to ease jet lag for travelers - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: Evaluating a 59.54% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Vanda Pharma says FDA is in violation of FDCA regarding its Hetlioz sNDA - The Pharma Letter
Will Vanda Pharmaceuticals Inc. stock outperform tech sector in 2025Candlestick Trading Patterns & High Yield Portfolio Picks - ulpravda.ru
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright Analysts Raise Earnings Estimates for VNDA - MarketBeat
FDA Grants Approval to Vanda Pharma’s Motion Sickness Medication, Boosting Growth Potential - Bitget
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance
VIX Spike: Can Vanda Pharmaceuticals Inc VM4 stock surprise markets with earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - moha.gov.vn
VNDA: HC Wainwright & Co. Raises Price Target to $22, Maintains Buy Rating | VNDA Stock News - GuruFocus
Gastric Motility Disorder Drugs Market is expected to reach US$ - openPR.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha
Vanda's tradipitant can significantly reduce nausea in those taking a GLP-1 - MSN
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley - Yahoo Finance
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus (NASDAQ:VNDA) - Seeking Alpha
After 40 Years, USFDA Approves Vanda Pharma's Motion Sickness Drug Nereus - Medical Dialogues
VNDA obtains FDA nod for motion sickness drug, stock gains - MSN
Vanda wins FDA approval for NEREUS motion sickness drug - MSN
Jefferies Initiates Vanda Pharmaceuticals(VNDA.US) With Hold Rating, Announces Target Price $7.5 - 富途牛牛
Vanda stock jumps with FDA approval of motion sickness drug - BioWorld MedTech
Vanda Pharmaceuticals hits 3-year high after FDA approves Nereus | Tap to know more | Inshorts - Inshorts
US FDA approves Vanda Pharmaceuticals' motion sickness drug - Reuters
D.C.-based Vanda gets FDA nod for motion-sickness treatment - The Business Journals
What's Going On With Vanda Pharmaceuticals Stock Wednesday?Vanda Pharmaceuticals (NASDAQ:VNDA) - Benzinga
Vanda Pharmaceuticals: Could Now Be A Good Time To Invest? - StocksToTrade
Vanda surges 28% after FDA approval - breakingthenews.net
B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $14 - 富途牛牛
B. Riley Securities Raises Price Target for VNDA to $14.00 Maint - GuruFocus
Vanda Pharmaceuticals price target raised to $14 from $11 at B Riley - MSN
Vanda Pharmaceuticals Inc. (VNDA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vanda Pharmaceuticals (NASDAQ:VNDA) Hits New 52-Week HighHere's What Happened - MarketBeat
Vanda Pharma's (VNDA) NEREUS Approval Boosts Growth Prospects - GuruFocus
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):